Therapy: Gastrointestinal safety of incretin therapies: Are we there yet?

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 11, 2016, Pages 630-632

  Meier, Juris J ^a   Rosenstock, Julio ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b Dallas Diabetes and Endocrine Center at Medical City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADVERSE OUTCOME; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GALLBLADDER DISEASE; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; TREATMENT REFUSAL; VOMITING;

EID: 84988674517     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.149     Document Type: Short Survey

References (10)

1. Meier J. J, & Nauck M. A. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 57, 1320-1324 (2014
2. Gale E. A. M. Smoke or fire? Acute pancreatitis, and the liraglutide trials. Diabetes Care 38, 948-950 (2015
3. Abbas A. S, Dehbi H. M, & Ray K. K. Cardiovascular, and non-cardiovascular safety of dipeptidyl peptidase 4 inhibition: a meta-Analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes. Metab. 18, 295-299 (2016
4. Azoulay L, et al. Association between incretin-based drugs, and the risk of acute pancreatitis. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2016.1522 (2016
5. Faillie J. L, et al. Association of bile duct, and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2016.1531 (2016
6. Meier J. J. GLP 1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742 (2012
7. Rosenstock J, et al. Efficacy, and safety of lixilan, a titratable fixed-ratio combination of lixisenatide, and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof of concept randomized trial. Diabetes Care 39, 1579-1586 (2016
8. Azoulay L. Incretin-based drugs, and adverse pancreatic events: almost a decade later, and uncertainty remains. Diabetes Care 38, 951-953 (2015
9. Davies M. J, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314, 687-699 (2015
10. Marso S. P, et al. Liraglutide, and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311-322 (2016